Skip to main content
. 2017 Jul 22;8(54):91860–91875. doi: 10.18632/oncotarget.19463

Table 1B. Meta-analysis results for associations between the TLRs and overall survival for ADC patients.*.

Univariate Multivariate
Gene Affy Probe ID n P value HR^ P value (gene)** HR (gene) P value (stage) P value (gender)
TLR1 210176_at 720 1.50E-03 0.63 (0.47-0.84) 0.0029 0.65 (0.48 - 0.86) 1.00E-15 ns
TLR2 204924_at 720 1.60E-08 0.43 (0.32-0.58) 1.00E-15 0.45 (0.33-0.6) 1.00E-15 ns
TLR3 206271_at 720 3.00E-04 0.59 (0.44-0.79) 0.0028 0.64 (0.48-0.86) 1.00E-15 ns
TLR4 232068_s_at 673 ns 0.76 (0.56-1.03) - - - -
TLR5 210166_at 720 0.0057 0.67 (0.5-0.89) 0.0066 0.67 (0.5 - 0.89) 1.00E-15 ns
TLR6 239021_at 720 0.00054 0.58 (0.43-0.79) 0.0049 0.64 (0.46 - 0.87) 1.00E-15 ns
TLR7 220146_at 720 2.90E-11 0.37 (0.27-0.5) 1.00E-15 0.41 (0.3 - 0.57) 1.00E-15 ns
TLR8 229560_at 720 0.0027 0.69 (0.54-0.88) 0.0014 0.6 (0.43-0.82) 1.00E-15 ns
TLR9 223903_at 673 ns 1.17 (0.87-1.59) ns - - -
TLR10 223751_x_at 720 ns 0.97 (0.78-1.23) - - - -

* For all significant TLRs, FDR 5% was tested, ADC combined samples P <0.0066; ** Multivariate for ADC for gender and stage; ^ Hazard ratio. Ns, not significant. Dash indicates test was not performed due to non-significance in univariate analysis.